2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 252

Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
Abstract Number: 253

Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month
Abstract Number: 254

NLRP12 Autoinflammatory Disease: A Chinese Case Series and Literature Review
Abstract Number: 255

Safety and Efficacy of Long-Term Canakinumab Therapy in Patients with CAPS: Final Results from Beta-Confident Registry
Abstract Number: 256

Muckle-Wells Syndrome in Chinese Adult Patients
Abstract Number: 257

CNS Manifestations of Patients with Muckle-Wells Syndrome
Abstract Number: 258

Unmet Psychosocial Needs in Patients with CAPS
Abstract Number: 259

Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience
Abstract Number: 260

Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Abstract Number: 261

Sarcoidosis Is Associated with Increased Risk of Venous Thromboembolism: A Population-Based Study
Abstract Number: 262

Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013
Abstract Number: 263

How Does Sarcoidosis Present in Spain? Characteristics at Diagnosis of 979 Patients from the Sarcogeas-SEMI Registry
Abstract Number: 264

Ethnicity-Related Differences in the Clinical Presentation of Sarcoidosis in Spain (SARCOGEAS-SEMI Registry)
Abstract Number: 265

Characterization of Eye Sarcoidosis with or without Systemic Involvement: Application of Iwos Criteria in an Uveitis Unit
Abstract Number: 266

Diffuse Idiopathic Skeletal Hyperostosis and Obesity- Is There a Causal Relationship?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].